Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

410 Study Matches

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers

Molecular-guided therapy for childhood cancer that has returned or is not responding to previous therapy.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 771-531-3097
All
All
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A diagnosis of pediatric cancer of varying types for which there is no known cure or disease that is not responding to treatment.
Must be over one year of age at enrollment.
Must be less than or equal to 21 years at initial diagnosis.
Must have measurable disease by accepted standards.
Tumor must be accessible for biopsy.
Exclusion Criteria:
Has received chemotherapy within the last 7 days of biopsy.
Has received any radiotherapy to the primary sample site within the last 14 days.
Currently taking any other study drug.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

AWS-PSU: Active Women's Study at Penn State University

AWS-PSU: Active Women's Study at Penn State University This research study is being conducted to evaluate the impact of exercise and reproductive function on bone strength. Eligible young women (age 18-30) are those that are generally healthy and either a) exercising and experiencing regular or irregular menstrual cycles, or b) not exercising and experiencing regular menstrual cycles.
Nicole Aurigemma at nca11@psu.edu or 814-863-4488
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Regular or irregular menstrual cycles
Age 18-30
BMI between 16-29.9
No hormonal contraception for 6 months
Exclusion Criteria:
Smoking
Currently using medication impacting bone
Food & Nutrition, Muscle & Bone, Women's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Evaluation of Concert Hall Acoustics Stimuli

The overall goal of the project is to better understand how people subjectively perceive differences in concert hall acoustics. Subjects will listening to musical passages, side-by-side, in aural simulations of being in different concert halls or rooms. Subjects will then be asked to provide subjective data about the different rooms in which they are listening. The passages may be rated on subjective parameters such as preference, reverberance, warmth, clarity, envelopment, intimacy, brightness, etc. The results from this research will help to better understand how concert-goers perceive different room, and will help acoustic consultants to better design concert hall in the future to produce more pleasing acoustic environments.
Matthew Neal at mtn5048@psu.edu
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must have normal hearing thresholds (tested at beginning of test)
Minimum 5 years of combinbed musical training (i.e. private lessons, ensembles, etc.)
Must be actively studying music or involved in a musical ensemble or group.
Exclusion Criteria:
Cannot have sigificant hearing loss (tested at beginning of test)
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Feasibility and acceptability of mind-body strategies to increase physical activity and reduce health disparities in rural breast cancer survivors

The purpose of this study is to explore feasibility and acceptability of mind-body strategies to increase physical activity and reduce health disparities in rural cancer survivors and inform the cultural-adaptation of a physical activity intervention for rural breast cancer survivors.
Scherezade Mama at hdpar@psu.edu or 814-863-0132
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age
Received a cancer diagnosis previously
Lives in central Pennsylvania
Exclusion Criteria:
Below the age of 18
No history of cancer
Lives outside of the Penn State Cancer Institute's 28-county catchment area
Prevention, Mental & Behavioral Health, Cancer
  Email this study information to me
  Contact the study team

Investigation of Remission in Rheumatoid Arthritis

This is an experimental observation study of Rheumatoid arthritis that will examine remission in rheumatoid arthritis by (1) collecting biospecimens of rheumatoid arthritis subsets with collection of clinical data and (2) investigation of etiology of immune tolerance in rheumatoid arthritis.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis by a Rheumatologist
Patient of Penn State Hershey Rheumatology
Exclusion Criteria:
No other connective tissue autoimmune disease other than Sjogren's Syndrome
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma and Medulloblastoma

A study if the safety and effectiveness of nifurtimox in children with neuroblastoma or medulloblastoma, that has returned or is not responding to treatment.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT00601003
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 0-21 years at the time of diagnosis.
Diagnosis of neuroblastoma or medulloblastoma.
Disease has not responded to previous treatment.
Disease is measurable bu accepted tests.
Exclusion Criteria:
Patients who weigh less than 3.5 kg (7.7 lbs).
Currently receiving another study drug.
Currently receiving other anticancer agents.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)

A study of DFMO for patients with neuroblastoma in remission.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02679144
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
A confirmed diagnosis of neuroblastoma.
Must be in complete remission (CR).
Tests and scans will be required to confirm remission.
Exclusion Criteria:
Patients below the defined minimum of height and weight.
Patients who are currently receiving another study drug may not participate.
Patients who are currently receiving other anticancer agents may not participate.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Phase I Study of Carfilzomib in combination with Cyclophosphamide and Etoposide for Children with Relapsed or Refractory Solid Tumors and Leukemias

A study of the safety of carfilzomib for children with solid tumors and leukemias that returned or did not respond to previous treatment.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT02512926
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of relapsed or refractory leukemia or solid timor.
Age 6 months to less than 30 years at enrollment.
Must be fully recovered from effects of previous treatment.
Life expectancy greater than or equal to 3 months.
Exclusion Criteria:
Prior treatment with carfilzomib.
Known allergy to Captisol®.
Down syndrome.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

The study is looking to find out more about how an investigational study drug called omecamtiv mecarbil works in people with heart failure. Omecamtiv mecarbil is also known as AMG 423. Omecamtiv mecarbil is an investigational medicine that increases the heart’s ability to pump.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02929329
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Hospitalized or an urgent ER visit for heart failure within the last 12 months.
Exclusion Criteria:
Age greater than 85 at the time of first study visit
Require dialysis
Require use of oxygen
Cancer requiring treatment within the last 5 years (Some exceptions may apply)
Unable to swallow pills
Heart & Vascular
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Nurse AMIE: A tablet based supportive care platform in Metastatic Breast Cancer (AMIE = Addressing Metastatic Individuals Everyday)

We propose to build and test a software program called Nurse AMIE (Addressing Metastatic Individuals Everyday) to be provided to Stage IV breast cancer patients on an electronic tablet. This program will be tested in 50 Stage IV breast cancer patients who live within the Penn State Cancer Institute’s 28 county catchment area. Goals of the Nurse AMIE are to regularly assess mental-health, physical health, and other symptom related needs among Stage IV breast cancer patients and to provide appropriate help via videos, weekly calls (face to face, tablet to tablet) with a patient guide at Penn State, and appropriate referrals to phone or in person visits (as needed). The proposed Nurse AMIE software program will allow for the plan of resources (videos, audio files, exercises) to help with many of the common symptoms and challenges experienced by the patients. This is an identified need on the part of both the patients and their medical care teams. Finally, it will also allow patient guides to check in with patients, review responses to surveys, decide whether new or different documents or videos are needed, and connecting the patient to palliative care and other services if additional care is found to be needed.
Female
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
metastatic breast cancer
ECOG<3
English speaking
sufficient vision/hearing or family support
Exclusion Criteria:
Medical or psychiatric conditions (beyond breast cancer, its treatment, and its symptoms) that would impair our ability to test study hypotheses (e. g. psychotic disorders, dementia, inability to give informed consent or follow the instruction).
Patients who are receiving any other behavioral intervention
Cancer
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B cell) Treated with Pegylated Asparaginase

A study to confirm and expand information on safety and effectiveness of apixaban to prevent blood clots as compared to no prevention treatment in children with newly diagnosed leukemia and lymphoma. This is a randomized study so patients will be selected by chance to be in either the group that receives apixaban or the group that does not receive apixaban.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT02369653
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
New diagnosis of leukemia (de novo ALL) or lymphoma (T or B cell).
An acceptable planned induction chemotherapy.
One year of age and older to less than 18 years of age.
Able to take oral medication or have it given through a tube.
Exclusion Criteria:
Had a blood clot in the past 3 months.
Known inherited bleeding disorder.
Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

A study to confirm and expand information on safety and effectiveness of defibrotide compared to best standard care to prevent veno-occlusive disease of the liver in adult and pediatric transplant patients. This is a randomized study so patients will be selected by chance to be in either the group that receives defibrotide or the group that does not receive defibrotide.
Suzanne Treadway, MS, RN, CCRP at streadway@pennstatehealth.psu.edu or 717-531-3097
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT02851407
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Must be older than 1 month of age.
Scheduled for a stem cell transplant and be at high risk of veno-occlusive disease.
Be at high risk of veno-occlusive disease.
Exclusion Criteria:
Unstable blood pressure.
Episodes of bleeding.
Blood Disorders, Children's Health, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Emerging relations between attention and negative affect in the first two years of life

The CAT Lab focuses on the ways in which emotion and attention interact to shape how children navigate through their social world. We do this through questionnaires and observations of behavior in our laboratory. This particular study will examine how children respond to emotional and social events. We ask infants and their parents to visit our lab 5 times, each visit being 4-6 months apart and usually lasting a little over an hour. During each visit to our lab, we ask infants to look at pictures of people and animals on a computer monitor while we record where their eyes are looking on the screen. Children also participate in several different games and play with different toys (just like those found in a common household such as balls, puppets, plastic animals, etc.). Some of these activities involve parents and some do not, but we do ask parents to stay in the room with their child for the full visit. During visits 2-5, we would also like to collect electroencephalogram (EEG) and respiratory sinus arrhythmia (RSA) data from your child. EEG measures the electrical activity in the brain using small metal sensors placed on the head with gel. RSA measures heart rate and breathing by placing small sensors on the torso. These procedures do not hurt, are low-risk, and provide real-time measurement of your child’s autonomic nervous system signals, much like an arm cuff measures blood pressure. When the sensors are removed, some children may feel like a bandage is being pulled off.
Norbert Promagan at nup21@psu.edu or 814-867-2322
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
infant is at least 3.5 months of age
infant born within +/- 3 weeks of due date
Infants without any serious medical complications
Infants of a healthy birth weight (>2500g; >5 lbs, 8 oz.)
Exclusion Criteria:
infant not of healthy gestational age
infants <2500g; <5lbs, 8 oz at birth
Infants who experienced any serious medical complications
Children's Health, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 2 locations

Study Locations

Hide all locations
Location
Harrisburg, PA
State College, PA

The effect of hyperoxia on coronary arterial collateral circulation

To examine the effect of 100% oxygen on the coronary blood flow of patients with coronary artery disease
Aimee Cauffman at acauffman@pennstatehealth.psu.edu or 717-531-1617
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
over 21 years of age
Patients with CAD who had recent heart cath
Healthy subjects
•no blood pressure or cholesterol meds
Healthy matched by gender, age, and BMI to CAD patients
Exclusion Criteria:
pregnant or nursing women
Chest pain or recent heart attack less than 6 months
Kidney disease
Chronic lung condition
Uncontrolled blood pressure
Heart & Vascular
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Predicting Concussion Outcomes with Salivary miRNA

The purpose of this study is to identify changes in salivary micro ribosomal nucleic acid (miRNA) expression that are predictive of symptom duration and severity following mild traumatic brain injury (mTBI) in children. The primary endpoints of this study are as follows: 1) Characterization of brain-related miRNA in the saliva of 250 children with mTBI and 200 age- and gender-matched controls between the ages of five and twenty-three years. 2) Identification of a set of salivary miRNAs that is predictive of duration and severity of mTBI symptoms.
Jessica Beiler at jbeiler@pennstatehealth.psu.edu
All
All
This study is also accepting healthy volunteers
NCT02901821
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
5 to 23 years of age
Seen in the Penn State Pediatric Concussion Clinic within 2 weeks of most recent concussion
Exclusion Criteria:
Does not speak english
Periodontal disease
Ongoing seizure disorder, or other neurologic disorder
Drug or alcohol dependency
clinical diagnosis of severe TBI
Children's Health, Neurology, Sports Medicine
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Young Children’s Representations of Parent-Child Negotiation

The goal of this study is to learn how young children think and tell stories about challenges between parents and children. Children will play games and tell stories using toys while caregivers fill out surveys and talk to researchers. This will occur twice, about 6 months apart. Qualities of children's stories, their language and regulation skills, demographic information about children and caregivers, and parenting behaviors will be examined.
Hannah Mudrick at hxm99@psu.edu or 717-948-6404
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Children between the ages of 5 and 7
At least one caregiver of a child between ages 5 and 7
English-speaking
Middle income
Caregiver at least 18 years old
Exclusion Criteria:
Caregivers that are not fluent in English
Children that are not fluent in English
Children who are unable to tell stories with a researcher due to developmental disability or language delay
Children who are younger than 5 or older than 7
Low or high income
Education, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Harrisburg, PA

RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion to assess Sustained effecTs Of dRoxidopa thErapy

This is a multi-site, placebo-controlled, double-blind, time to intervention study designed to evaluate the clinical efficacy and safety of droxidopa versus placebo over a 12-week double-blind treatment period in patients with symptomatic NOH who have previously received up to 16 weeks of open-label treatment with an individually optimized dose of droxidopa (randomized withdrawal design).
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02586623
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Symptomatic neurogenic orthostatic hypotension associated with: (1) primary autonomic failure (Parkinson’s Disease, Multiple System Atrophy, Pure Autonomic Failure), (2) Non-Diabetic Autonomic Neuropathy, or (3) Dopamine Beta Hydroxylase deficiency
Able to stand, with or without limited assistance
Exclusion Criteria:
History of heart attack within the past 2 years, congestive heart failure (class 3 or 4), or uncontrolled cardiac arrhythmia
High blood pressure that requires treatment with blood pressure medication
History of cancer within the past 2 years (some exceptions can be discussed)
Diabetic autonomic neuropathy
Women who are pregnant or breastfeeding
Neurology
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Biobehavioral Health Risk and Resilience in College Students (PSU THRIVE Study)

This protocol is designed to examine biobehavioral health risks, resilience, grit, forgiveness and well-being in college students.
Laura Klein at lcklein@psu.edu or 814-883-8624
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Fulltime undergraduate student
18 to 24 years of age
English is a primary language
Exclusion Criteria:
Not enrolled as a full time undergraduate student
Under age of 18 years
Over age of 24 years
Not comfortable speaking English
Mental & Behavioral Health
  Email this study information to me
  Contact the study team

A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™(UGN-101) on Ablation of Urothelial Carcinoma Lesions in the Upper Urinary Tract

This is a clinical trial, designed to determine safety &amp; effectiveness of and patient reaction to the use of MitoGel™ in the upper urinary system of patients with non-invasive low-grade (LG), urotheilal cancer (UTUC)
Kathleen Lehman at klehman3@pennstatehealth.psu.edu or 717-531-5930
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02793128
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least one (1) measurable and biopsy-confirmed papillary Low Grade tumor, evaluated visually, ≤ 15 mm.
ECOG (Eastern Cooperative Oncology Group) performance status <3 (with Karnofsky >40).
Life expectancy greater than 24 months.
Adequate organ and bone marrow function as determined by routine laboratory tests
New or recurrent patients with LG, non-invasive UTUC in the pyelocalyceal system.
Exclusion Criteria:
Patient received BCG treatment for UC during the 6 months prior to Visit 1.
The patient has untreated concurrent urothelial cancer in other locations other than the target area (unless treated during screening).
Carcinoma in situ (CIS) in the past in the urinary tract.
Patient has a history of invasive urothelial carcinoma in the urinary tract during the past 5 (Five) years.
Patient is actively being treated or intends to be treated with systemic chemotherapy during the duration of the trial.
Kidney & Urinary System, Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Monetary Reward Processing and Emotion Regulation in Adolescence: An fMRI pilot Study

This research is being done to identify patterns of brain activation underlying monetary reward processing and emotion regulation in adolescence, as well as correspondence between parent and adolescent neural activation. Children and their parents will complete questionnaires. Children will complete computer tasks during EEG and in an MRI scanner. Parents can also complete the MRI scan if interested.
All
Younger than 18 years old
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Ages 12--16 years
Fluent in English
No history of treatment for psychiatric disorders
Exclusion Criteria:
Intellectual or developmental disabilities
Visual or hearing impairments
Inability to complete MRI scan due a pacemaker, aneurysm clips or any metal in body (e.g., braces, surgical devices)
Currently pregnant or lactating
Neurological disease (e.g., stroke, tumor, Parkinson’s disease, etc.)
Children's Health, Neurology, Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Bioactive RNA in Infant Nutrition: A Novel Regulator of Developmental Origins and Allergic Response

Characterize longitudinal changes in immune-related ribonucleic acids (RNAs) during the first four months after birth (a critical period when protective breastfeeding benefits are conferred) and compare breast milk RNA exposure between atopic and non-atopic infants. Atopy, the genetic tendency to develop allergic diseases such as asthma and atopic dermatitis (AD), is present in nearly one-third of children. Atopy results from activation of the immune response to environmental exposures. The developmental origins that influence this response are not completely understood. Infants who breastfeed beyond three months have lower atopy risk. What factors in maternal breast milk (MBM) confer these health benefits and why is breastfeeding beyond three months so critical? The answer may be a bioactive factor in MBM called microRNA (miRNA). MiRNAs are small non-coding molecules that regulate gene expression across multiple tissues. There are nearly 1,000 types of miRNAs in MBM. The majority are found in the lipid or cellular milk fractions, and evidence suggests that they regulate metabolic and immune pathways. Studies by our lab and others demonstrate that MBM miRNA composition is influenced by both maternal factors (delivery method and weight) and infant factors (prematurity). Animal studies suggest nutritional miRNA influences the immune system through immune-modulation. Thus, breast milk miRNA exposure may mitigate infant atopy risk.
Jessica Beiler at jbeiler@pennstatehealth.psu.edu or 717-531-5656
Female
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
New breastfeeding mother
Mothers ages 18-50
healthy baby < 7 days old
seeking care at a Penn State Pediatric Clinic
Term baby 37-42 weeks at birth
Exclusion Criteria:
plan to move out of central PA within 1 year
plan to stop breastfeeding before baby is 4 months old
Children's Health
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Stress, Gene Expression, &amp; Disease Susceptibility

This research is being done to investigate the mechanisms linking early life stress to disease susceptibility. In order to better understand the underlying mechanism, we need to identify how target cells respond and adapt to stress. One way to test this mechanism is to see how specific genes are activated over a short period of time.
Megan Zinobile at muz144@psu.edu or 814-689-9017
All
18 year(s) or older
This study is also accepting healthy volunteers
NCT03637751
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Between the ages of 18 and 25
Must currently be a non-smoker
Cannot use medications on a regular basis besides oral contraceptives
Females must use oral contraceptives
Exclusion Criteria:
Cannot have a significant medical illness or endocrine illness
Cannot have had a recent infection or illness
Females cannot be pregnant or breastfeeding
Cannot be a current smoker
Mental & Behavioral Health
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant

A study of defibrotide to prevent acute GVHD. Subjects will be randomized to receive either defibrotide with routine prevention or to receive routine prevention alone.
Suzanne Treadway at streadway@pennstatehealth.psu.edu or 717-531-3097
All
All
This study is NOT accepting healthy volunteers
NCT03339297
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be ≥1 year and <75 years of age
A diagnosis of acute leukemia in remission
Exclusion Criteria:
Prior transplant
Acute bleeding
Cancer
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Effect of Group Led Creative Writing on Mood in Cancer Patients

The primary purpose of this study is to determine whether creative writing for cancer patients will have a positive impact on their mental health. Using a randomized controlled trial approach; we will be utilizing emotion thermometers to evaluate response on a number of domains such as anxiety, depression, despair and anger along with a series of survey questions to monitor changes in depressive and anxiety symptoms. Open-ended survey questions will be used to capture how this intervention impacts patient experience of their illness. Melissa Greene’s “Write from the Heart” program focuses more on creative writing rather than cancer focused topics. Patients in the intervention arm will have a minimum of four, 1.5 -hour group sessions with her over the span of two months. Patients in control arm will be provided a book (Writing Down Bones by Natalie Goldberg) about creative writing and will be asked to do activities for 1.5hrs every 2 weeks.
Darya Nesterova at dnesterova@pennstatehealth.psu.edu
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Adult >20 years of age
Has cancer diagnosis
Ability to understand English language and ability to write without any functional difficulty
ECOG performance status 0-3
Exclusion Criteria:
Inability to give informed consent
Severe psychiatry illness (e.g., uncontrolled depression, schizophrenia or psychosis
Severe cognitive impairment
Pregnant females
Inability to write or understand English
Cancer
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Hemodynamic-GUIDEd Management of Heart Failure (GUIDE-HF)

The GUIDE-HF Randomized arm is to determine if PA pressure-guided HF management using CARDIOMEMS improves health outcomes in NYHA Class II, III or IV heart failure patients with either elevated NT-proBNP and/or a prior heart failure hospitalization. The GUIDE=HF Single Arm is to determine the equivalence of the effect of PA pressure-guided HF management on health outcomes between NYHA Class III heart failure patients with elevated NT-proBNP only and those with a prior heart failure hospitalization only.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03387813
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
heart failure
heart failure hospitalization within 1 year
Medicare
Currently patient of HMC
Exclusion Criteria:
Currently on dialysis
Heart & Vascular
  Email this study information to me
  Contact the study team
  See more information
  Show all 2 locations

Study Locations

Hide all locations
Location
Hershey, PA
Reading, PA

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis

this study is looking for patients with compensated cirrhosis as the result of non-alcoholic steatohepatitis (NASH). ]). NASH is the result of too much fat within the liver, resulting in injury and death to individual liver cells; the presence of injury like this is followed by progressive formation (laying down) of liver fibrosis (scar tissue); the result of this is increased liver stiffness. As more and more fibrosis is formed and laid down in the liver, the outcome is cirrhosis. Compensated cirrhosis means the liver has become very scarred but can still perform many important bodily functions. This research is being done to find out how safe and effective the investigational drug (also called a study drug) obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by NASH (non-alcoholic steatohepatitis). Currently, there are no therapies approved for the treatment of NASH. OCA (the brand name is Ocaliva) has been approved in several regions in North Americacountries (including the United States,and Canada) and Europe) for the treatment of another form of chronic liver disease called Primary Biliary Cholangitis (PBC).
Laurie Peiffer at lpeiffer@pennstatehealth.psu.edu or 717-531-5226
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03439254
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
NASH with cirrhosis
willing to use contraception
Exclusion Criteria:
hepatic decompensation
history of liver transplant
significant cardiovascular disease
alcohol abuse
Digestive Systems & Liver Disease
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Standing Cognition and Co-morbidities of POTS Evaluation (SCOPE)

Healthy participants will complete cognitive tests while lying down and standing. Patients with POTS were previously recruited.
All
All
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
13 to 60 years old
healthy
Exclusion Criteria:
Inability to give, or withdrawal of, informed consent
Inability to stand
Any chronic or systemic illness
History of recurrent fainting
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Dermatomyositis: A patient’s perspective on living with the disease

Survey study and focus group to assess health anxiety and indirect costs for patients with dermatomyositis.
Melissa Butt at mbutt1@pennstatehealth.psu.edu or 717-531-6117
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age 18 years or older
Diagnosis of Dermatomyositis
Patient of Penn State Health
Exclusion Criteria:
A concurrent cancer dianosis (expect basal or squamous cell cancer)
Skin Conditions
  Email this study information to me
  Contact the study team

Accessibly of Conversational Agents with Deaf or Blind Users

Using small focus groups, this work aims to understand the experiences, challenges, perceptions, and opportunities for the use of conversational agents (e.g Amazon Alexa and Siri) for users with visual or hearing impairments, with the goal of developing more accessible and inclusive systems.
Johnna Blair at jlb883@ist.psu.edu or 814-706-8412
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Either, blind or visually impaired,
Or, hard of hearing or deaf using cochlear implant or other aided hearing device
Currently 18 years of age or older
English language speakers
Exclusion Criteria:
Minors, under the age of 18
Non-English language speakers
Language & Linguistics, Vision & Eyes
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
State College, PA

Site For Trial to Access Chelation Therapy TACT2

Site For Trial to Access Chelation Therapy TACT2
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT02733185
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
History of diabetes
History of myocardial infarction
Equal to or greater than 50 years of age
Exclusion Criteria:
Myocardial infarction within the past 6 weeks
Heart failure hospitalization within the past 6 months
Cigarette smoking within the past 3 months
Heart & Vascular, Diabetes & Hormones
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA